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Health-related quality of life after treatment for bladder cancer
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Samantha J Mason1,2, Amy Downing1,2, Penny Wright1, Luke Hounsome 3, Sarah E Bottomley4, Jessica Corner5, Mike Richards6,
James W Catto4 and Adam W Glaser1,2
BACKGROUND: Little is known about quality of life after bladder cancer treatment. This common cancer is managed using
treatments that can affect urinary, sexual and bowel function.
METHODS: To understand quality of life and inform future care, the Department of Health (England) surveyed adults surviving
bladder cancer 1–5 years after diagnosis. Questions related to disease status, co-existing conditions, generic health (EQ-5D), cancer-
generic (Social Difﬁculties Inventory) and cancer-speciﬁc outcomes (Functional Assessment of Cancer Therapy—Bladder).
RESULTS: In total, 673 (54%) patients responded; including 500 (74%) men and 539 (80%) with co-existing conditions. Most
respondents received endoscopic treatment (60%), while 92 (14%) and 99 (15%) received radical cystectomy or radiotherapy,
respectively. Questionnaire completion rates varied (51–97%). Treatment groups reported ≥1 problem using EQ-5D generic
domains (59–74%). Usual activities was the most common concern. Urinary frequency was common after endoscopy (34–37%) and
radiotherapy (44–50%). Certain populations were more likely to report generic, cancer-generic and cancer-speciﬁc problems;
notably those with co-existing long-term conditions and those treated with radiotherapy.
CONCLUSION: The study demonstrates the importance of assessing patient-reported outcomes in this population. There is a need
for larger, more in-depth studies to fully understand the challenges patients with bladder cancer face.
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INTRODUCTION
Bladder cancer (BC) is the 9th most common cancer in the
United Kingdom and one of the most expensive malignancies to
manage.1,2 The disease is best stratiﬁed according to the
presence of muscle invasion and cellular differentiation. Most
BCs are non-muscle invasive (NMIBC) and have an excellent
long-term prognosis.3 NMIBC tumours are managed by endo-
scopic resection, intravesical chemotherapy and long-term
surveillance.4 Following initial treatment, many patients develop
local recurrence, requiring further treatments.5 Around 1/3 of
tumours are muscle invasive BCs (MIBCs), requiring radical
treatment if cure is to be obtained. Radical cystectomy (RC) or
radiotherapy includes treatment of adjacent viscera with
regional lymph nodes, and often includes systemic chemother-
apy. The nature and toxicity of treatments and surveillance for
BC can vary between patients, between each option and over
time. There is evidence that treatment for MIBC can impact upon
urinary function,6 bowel function,7 sexual function,8,9 and affects
body image,10,11 which can lead to anxiety and depression.7
However, there is less evidence regarding the consequences of
treatment for NMIBC and the impact on patients' Health-Related
Quality of Life (HRQL).12,13
The importance of large scale, population-level Patient-
Reported Outcome Measures (PROMS) in improving healthcare
design, patient experience and directing care is becoming
recognised.14,15 PROMS can be used to ascertain a more
comprehensive understanding of the quality of survival, alongside
the impact and relevance of health care provision, and as a
surrogate measure within clinical trials. Previous research in the
USA used a linkage database to identify BC patients and looked at
results of 620 surveys completed before diagnosis and 856
completed after by patients ≥65 years old.16 European PROMs
work included 823 German patients of all ages and stages of BC.13
These cross-sectional studies used generic PROMs or generic
cancer PROMs.
To date, no large-scale surveys of BC patients have been
conducted in the United Kindgom. As such, in 2013 the
Department of Health (DH) England designed and
administered a pilot survey of patients 1–5 years following
their initial treatment for BC. Here we report the results of the
pilot survey, which was conducted to identify a methodology to
deﬁne the HRQL of individuals in the years following their
treatment and to identify potential factors associated with poor
outcomes.
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METHODS
Survey design
The DH methodology has been described previously for cohorts
diagnosed with non-Hodgkin’s lymphoma, breast, colorectal and
prostate cancer.17 Individuals aged 16 or older surviving 1–5 years
after a diagnosis of BC were identiﬁed via the Eastern Cancer
Registration and Intelligence Centre (now part of National Cancer
Registration and Analysis Service, NCRAS).18 The sample size was
chosen to match similar studies performed by the DH in other
cancer sites.17
Identiﬁed participants were mailed a questionnaire, with a
covering letter from their treating Cancer Centre. Consent to
participate was implied through return of completed question-
naires. Individuals who did not want to participate were asked to
return their questionnaire uncompleted or to discard the survey.
Two reminders were sent to non-responders. A Freephone
helpline for patients was provided, which supported completion
of the survey. Permission to approach patients without informed
consent was given by the Health Research Authority (ref ECC 5-02
(FT7)/2012).
Survey content
Survey content included questions about treatment, disease
status, generic HRQL (EQ-5D-5L) and BC speciﬁc outcomes
(Functional Assessment of Cancer Therapy—Bladder (FACT-Bl)),
social problems (Social Difﬁculties Inventory (SDI-21)), health and
well-being in the past month, experience of care and presence of
other long-term conditions (LTCs) (Supplementary File 1).
The EQ-5D-5L records problems on ﬁve domains (mobility, self-
care, usual activities, pain/discomfort and anxiety/depression).19,20
There are ﬁve response options ranging from no problems to
extreme problems. Respondents are asked to complete the
response options based on how they are feeling that day.
The SDI-21 is a 21-item questionnaire, developed to assess
everyday problems experienced by cancer patients.21 Questions
are answered on a scale of 0 (no difﬁculty) to 3 (very much), with
respect to the past month. Sixteen of the items form three
subscales: Everyday Living, Money Matters and Self and Others.
These scales form a measure of social distress (SD-16), with scores
ranging from 0 to 44.22 The SDI-21 also comprises ﬁve single
items.
FACT-Bl consists of the 27-item FACT-General (FACT-G) ques-
tionnaire23 and 13 additional items. FACT-G covers four areas;
Physical well-being, Social/family well-being, Emotional well-being
and Functional well-being. The 13 additional items relate to
urinary issues, bowel issues, appetite and weight, sexual items,
body image, a question asking if the respondent has an ostomy
appliance and two questions about ostomy appliances. All items
ask about the last 7 days.
These surveys were chosen for inclusion as EQ-5D-5L, SDI-21
and Functional Assessment of Chronic Illness Therapy (FACIT)
modules have been used in similar studies performed by the DH in
other cancer sites.17,14 Cognitive testing of all questionnaires was
performed with a group of volunteer patients and expert panel
review (clinicians/methodologists). In the ﬁnal version of the
survey, the team designing the survey removed the 'somewhat'
response option from FACT-Bl; changing the questionnaire from
ﬁve responses to four.18
Data handling
All variables were derived from the survey data. Participants were
asked if they had any other LTCs at the time of completing the
questionnaire and to tick all conditions that they had from a list
widely used in English DH surveys. This variable was categorised
into none, 1, 2 or ≥3 LTCs. Information on self-reported disease
status (in remission, treated but still present, not treated,
recurrence, and not certain) and treatments (endoscopic/tele-
scopic surgery with or without chemotherapy directly into the
bladder, RC, chemotherapy, and radiotherapy) was taken from the
questionnaire. Age was grouped into <55 years, 55–64 years,
65–74 years, 75–85 years and ≥85 years.
EQ-5D-5L responses were split into people who reported at
least one problem (of any severity) on any domain and people
who reported having no problems on any domain. Individual
domains were categorised in this way. A validated cutoff score of
≥10 on the SD-16 scale indicates a high level of social difﬁculties
that requires follow-up by health or social care staff.24 This was
used in our analysis as a cutoff point (socially distressed v not
socially distressed). Estimated cutoff points of 5 for the Everyday
Living subscale, 2 for the Money Matters subscale and 3 for the
Self and Others subscale were used in this study, as per previous
research.25 The ﬁve single items of the SDI-21 are scored
individually.22 As the 'somewhat' option was removed from the
questionnaire, FACT-Bl scores could not be calculated as per
normal practice and thus cancer-speciﬁc questions from FACT-Bl
were examined separately. FACT-Bl responses were grouped into
those who responded 'not at all' or 'a little' and those who
responded 'quite a bit' and 'very much'. Outcomes pertaining to
well-being, urinary items, sexual items and body image are
presented here.
Statistical analysis
Descriptive statistics were used to report respondent character-
istics, EQ-5D-5L responses, SD-16 scores, SDI-21 subscale scores
and FACT-Bl responses. Outcomes were analysed in relation to
age, sex, other comorbidities and type of treatment using χ2 tests.
Statistical signiﬁcance was set at the 1% level to minimise the
chances of false-positive associations. Analyses were performed
using Stata version 15 (Stata, College Station, TX).
RESULTS
Survey population
In total, 1252 BC patients were randomly identiﬁed and sent a
questionnaire (Fig. 1). Of these, 21 (2%) died during the survey
period, leaving 1231 eligible patients. Questionnaires were
returned by 673 people (54% response rate), including 500 (74%)
men and 162 (24%) women (Table 1). Most respondents were
white (93%) and were in remission from BC (65%). Co-existing LTCs
were common (80% reported ≥1 LTC and 29% reported ≥3). The
most common treatment was endoscopy/telescopy (31%). Radical
treatment was reported by 28% of respondents: of which 14% had
undergone RC, 9% had received external beam radiotherapy and
5% had radiotherapy with intravenous chemotherapy. Other
treatment combinations were given to <2% of respondents and
therefore excluded from analysis. A stoma was present in 16% of
respondents. Of the radical treatments, patients ≥85 years were
more likely to be treated with radiotherapy (31%) (Supplementary
Table 1).
Respondent and non-respondent characteristics were com-
pared, using data from NCRAS (Supplementary Table 2). Indivi-
duals older than 85 years (RR, 39%) were less likely to participate.
Data quality
Most patients answered questions relating to sex, LTCs and
treatment (<5% missing responses). Of all the PROMs, FACT-Bl had
the largest variety of completion rates for items and scales; with
missing responses ranging from 5 to 49% (Supplementary
Table 3).
Generic HRQL
Overall, 65% of respondents reported ≥1 problem on any EQ-5D-
5L domain (Table 2). The percentage of respondents from
treatment groups reporting ≥1 problem on any EQ-5D-5L domain
ranged from 59% for endoscopy/telescopy and intravesical
chemotherapy to 74% for radiotherapy. Problems with usual
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activities were most commonly reported (43%). Respondents
treated with radiotherapy reported more problems with mobility,
self-care and usual activities compared to respondents who
received other treatments. Respondents with endoscopy/tele-
scopy were more likely to report problems with mobility than
respondents treated with endoscopy/telescopy and intravesical
chemotherapy (47% compared to 26%, p < 0.01).
Respondents aged ≥85 years were most likely to report some
problems with mobility, self-care and usual activities. Respondents
<55 years old were signiﬁcantly more likely to report problems
with anxiety/depression, with half of this group reporting some
problems, compared to between 31–44% of other age groups (p
= 0.01). Those with ≥3 LTCs reported signiﬁcantly more problems
on all EQ-5D-5L domains bar one (anxiety/depression).
Social difﬁculties
SD-16. Overall, 15% of respondents were classed as socially
distressed (score ≥10, Table 3). No differences were observed by
sex or age group. The respondents most likely to report
signiﬁcantly high social distress were those treated with radio-
therapy and respondents with ≥3 LTCs; with more than a quarter
of respondents from these groups meeting the criteria. Respon-
dents with a stoma were twice as likely to be socially distressed
compared to respondents without a stoma.
SDI-21 subscales. Difﬁculties with Everyday Living (score ≥5) were
reported by 21% of respondents (Table 3). Respondents treated
with radiotherapy and those who had ≥3 LTCs reported a higher
level of difﬁculty with Everyday Living (both 41%). Comparatively
fewer patients receiving other treatments reported difﬁculties
(≤25%). When comparing patients who did not have radical
treatments, signiﬁcantly more respondents with endoscopy/
telescopy reported difﬁculties with Everyday Living than respon-
dents treated with endoscopy/telescopy and intravesical che-
motherapy (23% compared to 11%, p < 0.01). Difﬁculties with
Everyday Living did not vary by sex, age group or stoma status.
Difﬁculties with Money Matters (score ≥2) were reported by
14% of respondents. This difﬁculty was signiﬁcantly more likely to
be reported by respondents who were <55 years of age (42%
compared to between 3 and 23% of other age groups, p < 0.01).
Differences were not found for treatment type, disease status,
stoma status, LTCs or sex (Table 3).
Difﬁculties with Self and Others (score ≥3) were reported by
17% of respondents. Reporting of signiﬁcant difﬁculties with Self
and Others was high in respondents <55 years of age, where more
than a third (34%) reported difﬁculties (Table 3).
SDI-21 single items. The most commonly reported difﬁculty was
with travelling or plans to take a holiday; reported by 33% of
respondents. Respondents with a stoma were signiﬁcantly
1,252 Patients sent to survey
673 (54%) responses
21 died
9% Radiotherapy (avg. age 78 years and 73% male)
5% Chemoradiotherapy (avg. age 66 years and 67% male)
14% Radical cystectomy (avg. age 65 years and 67% male)
29% Endoscopy & chemotherapy (avg. age 68 years and 72% male)
31% Endoscopy (avg. age 72 years and 84% male)
7.1% Other (avg. age 65 years and 77% male)
Completed:
• Personal details (98%)
• LTCs  (97%)
• Treatment details (96%)
• EQ-5D-5L (95%)
• SDI-21 (88–97%)
• FACT-Bl (51–95%)
Fig. 1 Design and response rates within this survey
Table 1. Demographics of survey respondents
Demographic No. of respondents %
Age, years
<55 53 7.9
55–64 137 20.4
65–74 247 36.7
75–84 184 27.3
≥85 35 5.2
No response 17 2.5
Sex
Male 500 74.3
Female 162 24.1
Not known 11 1.6
Race
White 667 99.1
Non white 6 0.9
No. of long-term conditions (LTCs)
None 111 16.5
1 205 30.4
2 141 21.0
≥3 193 28.7
Not reported 23 3.4
Disease status
Remission 434 64.5
Treated but cancer still present 42 6.2
No treatment 2 0.3
Recurrence 30 4.5
Not certain 85 12.6
Not reported 80 11.9
Treatment
Endoscopy/telescopy 207 30.8
Endoscopy/telescopy with chemotherapy
directly into the bladder
198 29.4
Radical cystectomy 92 13.7
Radiotherapy and Intravenous
chemotherapy
36 5.3
Radiotherapy 63 9.4
Other 48 7.1
Not reported 29 4.3
Stoma status
Stoma 108 16.0
No stoma 437 65.0
Not reported 128 19.0
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more likely to report 'quite a bit' or 'very much' difﬁculty with
this item than those without a stoma (29% compared to 15%, p
< 0.01).
Difﬁculties with sexual matters were reported 'quite a bit' or
'very much' by 15% of respondents. This difﬁculty was
signiﬁcantly more likely to impact on men, 17% of whom
reported 'quite a bit' or 'very much' difﬁculty compared to 5% of
females (p < 0.01).
Cancer-speciﬁc HRQL
Physical well-being. Overall, 25% of the cohort responded that
they experienced a lack of energy 'quite a bit' or 'very much', but
this was higher in respondents treated with radiotherapy (43%)
(Table 4).
Pain was reported 'quite a bit' or 'very much' by 10% of
respondents and was higher in respondents with ≥3 LTCs (19%)
(Table 5).
Social/family well-being. Of the 51% who answered this item, two
thirds (67%) reported dissatisfaction with their sex life ('not at all'
or 'a little' satisﬁed with their sex life). Dissatisfaction was
signiﬁcantly more likely to be reported by patients who under-
went RC surgery compared to those who had other treatments
(Table 4). A higher percentage of females reported that they were
'quite a bit' or 'very much' satisﬁed with their sex life (51%
compared to 31% of males, p < 0.01).
Emotional well-being. Respondents across the cohort reported a
lack of satisfaction with how they were coping with their illness, as
almost three-quarters of respondents reported that they were 'not
at all' or 'a little' satisﬁed. Feeling 'quite a bit' or 'very much'
nervous was reported by 10% of respondents; particularly by
females (18% compared to 7% of males, p < 0.01), and those with
≥3 LTCs (Table 5).
Functional well-being. Around a third of respondents (35%)
answered 'not at all' or 'a little' about their ability to work.
Respondents treated with radiotherapy were less likely to be able
to work compared to respondents receiving other treatments
(Table 4).
Although three quarters of respondents reported that they were
content with the quality of their life right now (reporting 'quite a
bit' or 'very much'), respondents with ≥3 LTCs were signiﬁcantly
more likely to report that they were not content (Table 5).
Bladder cancer-speciﬁc items
Urinary items: Urinating more frequently than usual was
common after endoscopy (reported 'quite a bit' or 'very much'
in 34–37%) and radiotherapy (reported 'quite a bit' or 'very much'
in 44–50%) (Table 4).
Sexual items: Disinterest in sex was reported by 66% of
respondents and had a good response rate of 85%. Disinterest
in sex was signiﬁcantly higher in females than males, with 86% of
females saying they were 'not at all' or only 'a little' interested in
sex, compared to 60% of males (p < 0.01). This difference was
observed (but not signiﬁcant due to small numbers) when
restricted to those who had a stoma, with 89% of females saying
they were 'not at all' or only 'a little' interested. Ability to maintain
an erection was less likely in males who had a stoma, with 96%
reporting 'not at all' or 'a little' to this item, though the result was
not signiﬁcant due to small numbers.
Body image: Just under half of respondents said that they didn’t
like their body appearance at all, or only liked it a little (48%).
Respondents with a stoma were more likely to report not liking
their body at all or only liking it a little (60% compared to 46% of
respondents without a stoma, p= 0.01).
DISCUSSION
Here we report HRQL in individuals between 1 and 5 years post
diagnosis for BC. While modest in size compared to PROMs studies
in other cancer sites, this work represents the largest UK study to
date and demonstrates this methodology is feasible in this
population. We have identiﬁed that reduced HRQL is common in
patients following BC treatment, that there are differences
according to treatment modality and patient characteristics, and
that further more focused studies are warranted.
Several key ﬁndings deserve discussion. First, our results
highlight the need to support people who have pre-existing
health conditions and a new diagnosis of BC. Respondents with
LTCs were much more likely to report poor HRQL across all EQ-5D-
5L items, all domains apart from Money Matters on the SDI-21, SD-
16 and on multiple items of FACT-Bl. The design and methodology
used in this survey limits our ability to investigate this further and
to understand whether this reﬂects the impact of BC on other
LTCs, or the impact of other LTCs on HRQL. This is an important
area for future studies to focus on.
Second, while we do not know details of each tumour (i.e., stage
or grade), most patients (60%) received only endoscopic surgery.
To date, most BC HRQL reports have focused upon MIBC and
cystectomy outcomes. As such, our data are the ﬁrst to look at
HRQL in MIBC and NMIBC outcomes across a UK population. When
comparing NMIBC treatments, overall, respondents receiving
endoscopic surgery with intravesical chemotherapy had higher
HRQL and fewer everyday living difﬁculties than those receiving
only endoscopic surgery. This may reﬂect recall bias (guidelines
suggest that most patients should have received intravesical
chemotherapy),4 performance status (unﬁt patients did not
receive intravesical chemotherapy), treatment differences (intra-
vesical chemotherapy improves disease outcomes) or service
design (perhaps better designed services are more guideline
compliant and more likely to support patients through treatment).
Support for patient selection has shown that for many domains
the HRQL was superior for combined treatment rather than just
endoscopic surgery.
Third, around 30% of respondents received radical therapy,
including 16% who had a stoma and 9% who had received
radiotherapy. The latter were most likely to report low HRQL,
problems with mobility, self-care and usual activities. They were
also more likely to be socially distressed (score ≥10 on SD-16),
have high levels of difﬁculty with everyday living, report a lack
of energy and an inability to work. Patients treated with
radiotherapy were also more likely to report needing to urinate
more frequently than usual. While these ﬁndings may reﬂect
outcomes from radiotherapy, when compared to RC, it is more
likely they reveal treatment patterns and pre-existing ﬁtness.26
Evidence to support this is that most of these measures were
better for patients who received both radiotherapy with
chemotherapy (for which higher ﬁtness is needed). Indeed
outcomes from RC and radiotherapy with chemotherapy were
broadly comparable to each other and to patients receiving only
endoscopy/telescopy.27 Finally, overall there were some
encouraging ﬁndings with social distress generally being low
in respondents, as 85% were below the cutoff point, and perfect
health (i.e., no problems on EQ-5D-5L) was reported by 35% of
respondents.
This study has a number of key limitations. Response rates were
marginally lower than for UK surveys in other cancer sites (63% for
colorectal cancer)14 and 68% overall for a pilot study of individuals
diagnosed with non-Hodgkin’s lymphoma (62%), breast (68%),
colorectal (64%) and prostate cancer (69%)).17 This may reﬂect the
BC population (i.e., typically more deprived, more manual workers
and lower literacy rates than other cancers).28 While respondents
were willing to answer personal questions, response rates for
sexual items were lower than for other domains. Details of disease
stage were not available and treatment details were self-reported
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(and not veriﬁed from other sources) thereby reducing ability to
interpret data in detail.
A major limitation was the removal by the survey developers of
the 'somewhat' response option from the FACT-Bl questionnaire,
which meant that composite scores could not be calculated, thus
affecting the interpretation of results. Although the removal of
response options from validated measures is not considered good
measurement practice, we were still able to gain important
information about patients who had few or no problems and
patients who had severe problems with individual items. Despite
this limitation, it was considered important to present the ﬁndings
as there is a lack of large-scale studies looking at all BC populations.
A further limitation was that, as it was a pilot study, the sample was
randomly identiﬁed, rather than population-based.
The results have been presented descriptively and multivariable
analysis was not undertaken. The small number of respondents in
some subgroups (e.g., in some of the treatment groups) and the
lack of information on important confounders (such as a measure
of socioeconomic deprivation) make it difﬁcult to obtain robust,
meaningful results.
Although more detailed analysis could not be carried out in this
study, it is important that future studies aim to incorporate this. In
particular, quantifying the impact of treatment-related issues (e.g.,
urinary, bowel, sexual problems or fatigue) on HRQL and social
distress is hugely important, as this will further highlight the
support and care needs of this group of patients, and indicate
where there are gaps in service provision.
Recent qualitative work highlighted gaps in the understand-
ing of HRQL of BC patients (particularly patients with NMIBC).12
Important themes included post-treatment experiences in terms
of family/friend support networks, dealing with incontinence,
voiding and catheterising, the 'new normal' (e.g., coping with
their post-surgery body), changing sexuality and living with the
lifelong threat of cancer.12 Although the authors recommend
longitudinal qualitative work with BC patients, based on the
results of the DH study, there is also a need to undertake
quantitative work to understand how HRQL changes in BC
patients over time. Future work should aim to identify both high
risk groups and treatment-related items with the biggest impact
on HRQL. This could potentially lead to PROMs being used as
part of routine practice, with risk factors for low HRQL monitored
in clinic.
A further recommendation for future BC PROMs work using
FACT-Bl is to include some validation work within the analysis.
Although FACT-G is widely considered to be a reliable and valid
tool to use with cancer patients, the bladder cancer-speciﬁc items
require psychometric analysis to understand how useful these
items are for use with BC populations. Alternatively, clinicians and
researchers may choose other BC speciﬁc measures, such as the
Bladder Cancer Index (BCI),29 or the European Organisation
for Research and Treatment of Cancer (EORTC) NMIBC and MIBC
modules.30,31
These data represent the largest PROMs study to use BC speciﬁc
PROMs. The results have highlighted groups at high risk of
signiﬁcant adverse consequences following BC diagnosis. How-
ever, there is a need to carry out larger in-depth population-based
HRQL studies of BC patients to fully understand the extent of the
morbidity burden experienced by survivors of BC.
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